SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, amended upper-limb data and recent commercial-launch job postings. Many expect approval and anticipate short covering, while others stress that hiring and FDA rare-disease messaging are not proof of a favorable decision and point to the prior setbacks and remaining efficacy questions.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA approval of a competing RRP treatment has fueled debate over the threat to Precigens PAPZIMEOS and whether the selloff is an overreaction; traders disagree on the therapies relative advantages and Precigens commercial head start. Attention is also turning to upcoming PRGN-2009 clinical data and a Q3 business update.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Shares are climbing to a fresh 52-week high as traders position ahead of the expected Q3 report, with BRIUMVI sales growth supporting optimism. Some also speculate about a potential buyout or short squeeze, but the takeover chatter is unconfirmed, and others attribute the move to earnings expectations and momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas announced addition to the S&P 500, replacing Kenvue, is drawing attention, with traders weighing index-related buying against a possible sell-the-news reaction. Some posts also raise unverified claims about a DHS-related breach, but they do not appear to be the main catalyst.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA reimbursement contribution for DefenCath could decline through 2027 is driving the sharp selloff and debate over future revenue. Some traders view the comments as a serious pricing risk, while others argue DaVitas estimates are preliminary and point to CMSs more favorable payment assumptions; several describe the decline as an overreaction.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers upcoming quarterly earnings report is the main focus, with traders watching whether results and guidance can support the recent rally. Sentiment is split between hopes for an earnings beat and renewed strength in big pharma, and concerns about the companys growth outlook and patent expirations.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Lines stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders debating whether heavy short interest could amplify the move. The reaction is mixed: some see evidence of a turnaround, while others point to profit-taking, fuel-cost pressures and lingering concerns about bookings and yields.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reaching its prespecified 80th death event triggered final analysis and heightened anticipation of topline results for its GPS treatment in AML. Traders are sharply divided: bulls see potential for strong survival data, while skeptics question the trials control-arm assumptions and point to the share-price weakness as a reason for caution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq selloff has put QQQ in correction territory, with traders linking the pressure to weakness across technology and AI-related stocks, worries about returns on heavy AI spending, and rising-rate concerns. The community is split between bears expecting further losses and dip-buyers anticipating a relief bounce or short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seeking Tactical Opportunities? These ETFs Are Worth Watching

With inflation, geopolitics and AI risks clouding the outlook, these ETFs offer tactical ways to navigate short-term market opportunities.

Are the Odds of a Fed Rate Hike Rising? ETFs Worth Watching Now

A hawkish Fed may not be off the table. Despite a recent pullback, Fed hike bets remain elevated. Here we present some ETFs that could benefit.

Seeking Short-Term Opportunities? ETFs for Tactical Investors

As investors grapple with inflation, AI-trade concerns and geopolitical risks, these ETFs could offer tactical opportunities.

Gold ETFs Slide Deeper: More Short-Term Pain but Long-Term Gain?

Gold ETFs slump amid rising yields and a strong dollar, but easing inflation risks, central bank demand and de-dollarization may fuel long-term upside.

Here’s how Wall Street analysts forecast gold prices

Investing.com -- Wall Street may be underestimating gold prices by clinging to outdated forecasting tools, Bernstein said that makes a bullish case for the metal hitting $3,700 an ounce by 2026.Analysts at Bernstein analyzed 15 common methods used to predict gold prices and found that most no longer work, or never really did. Instead, Bernstein identified six methods that remain useful, many of which focus on government and monetary policy rather than traditional commodity fundamentals.

TSX seen lower after Trump ramps up trade war with Canada

UBS answers top 10 investor questions on U.S. markets

Investing.com -- UBS strategists addressed key concerns from clients in their latest “House View Briefcase” report, touching on recent debates over the U.S. fiscal outlook, market positioning, and global opportunities.

European oil and defense stocks slip amid Israel-Iran ceasefire

Investing.com - Shares in European energy and defense stocks fell on Tuesday following U.S. President Donald Trump’s announcement of a ceasefire between Israel and Iran.

Will geopolitics actually have a market impact this time?

Investing.com -- Markets are once again shrugging off geopolitical uncertainty, raising the question, will it be different this time? According to Deutsche Bank, the answer is: not yet.Despite a dramatic escalation in the Middle East, including Israeli strikes on Iranian nuclear sites, the global market response has been modest. The reaction has so far been limited to commodities and regional equities.Oil jumped more than 7% on Friday, gold hit a record high, and Middle Eastern equities fell. But elsewhere, investors remained calm.

ProShares Trust II - ProShares UltraShort Gold -2x Shares

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

GLL ProShares UltraShort Gold

Fundamentals

Latest GLL News